Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial

<strong>Background<br></strong> Aspirin is widely used for cardioprotection with its antiplatelet effects due to the blocking of thromboxane A2 production. However, it has been suggested that platelet abnormalities in those with diabetes prevent adequate suppression with once daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parish, S, Buck, G, Aung, T, Mafham, M, Clark, S, Hill, M, Collins, R, Bowman, L, Armitage, J
Otros Autores:	ASCEND Study Collaborative Group
Formato:	Journal article
Lenguaje:	English
Publicado:	BioMed Central 2023

Ejemplares similares

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
por: Sarah Parish, et al.
Publicado: (2023-03-01)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
por: Aung, T, et al.
Publicado: (2017)

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
por: Petrucci, G, et al.
Publicado: (2024)

Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2
por: Angela van der Plas, et al.
Publicado: (2018-01-01)

Urinary leukotriene E4 and 11-dehydro-thromboxane B2 excretion in children with bronchial asthma
por: Kaori Yoshikawa, et al.
Publicado: (2004-01-01)

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
por: Rocca, B, et al.
Publicado: (2020)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
por: Parish, S, et al.
Publicado: (2022)

Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study
por: Wojciech Szczeklik, et al.
Publicado: (2016-08-01)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
por: Sammons, E, et al.
Publicado: (2024)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
por: Bowman, L, et al.
Publicado: (2017)

ASCEND-eye: rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
por: Sammons, E, et al.
Publicado: (2023)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
por: Sammons, EL, et al.
Publicado: (2024)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
por: Sammons, EL, et al.
Publicado: (2024)

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
por: Emily Sammons, et al.
Publicado: (2023-10-01)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
por: Emily L. Sammons, et al.
Publicado: (2024-11-01)

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
por: Mafham, MM, et al.
Publicado: (2019)

ASCEND-Eye: effects of omega-3 fatty acids on diabetic retinopathy
por: Sammons, E, et al.
Publicado: (2023)

Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
por: Clarke, R, et al.
Publicado: (1991)

Effects of Aspirin and Prednisone on Platelet Function and Thromboxane Synthesis in Healthy Dogs
por: John M. Thomason, et al.
Publicado: (2019-11-01)

Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation
por: Giovanna Petrucci, et al.
Publicado: (2022-12-01)

Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
por: Thomas J Montine, et al.
Publicado: (2010-02-01)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
por: Harper, C, et al.
Publicado: (2021)

Total synthesis of dehydro-boscialin glucoside
por: Karsten Krohn, et al.
Publicado: (2006-09-01)

Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B2 and 8-iso-prostaglandin F2α, levels in human urine samples by validated enzyme immunoassays
por: Giovanna Petrucci, et al.
Publicado: (2024-03-01)

Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples
por: Giovanna Petrucci, et al.
Publicado: (2024-11-01)

Aspirin affects early phases of metastasis through the inhibition of COX-1-thromboxane A2 axis
por: Lucotti, S
Publicado: (2016)

Effects of aspirin for primary prevention in persons with diabetes mellitus
por: Bowman, L, et al.
Publicado: (2018)

Aspirin resistance status as determined by urinary thromboxane B2 (TXB2) level in patients with ischemic heart disease and its relationship with Severity of coronary artery disease
por: Naghmeh Ziaie, et al.
Publicado: (2011-01-01)

Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2
por: Lucotti, S, et al.
Publicado: (2019)

Sustainable Triazine-Based Dehydro-Condensation Agents for Amide Synthesis
por: Roberto Sole, et al.
Publicado: (2021-01-01)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
por: Harper, C, et al.
Publicado: (2021)

Aspirin for primary prevention of vascular disease in people with diabetes.
por: Haynes, R, et al.
Publicado: (2009)

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
por: Guillaume Marquis‐Gravel, et al.
Publicado: (2024-02-01)

Thromboxane Modulates Endothelial Permeability
por: J. M. Klausner, et al.
Publicado: (1994-01-01)

Stability of thromboxane in blood samples
por: Helgadóttir H, et al.
Publicado: (2019-06-01)

Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
por: Aung, T, et al.
Publicado: (2016)

Effects of omega−3 fatty acid supplements on arrhythmias
por: Parish, S, et al.
Publicado: (2020)

Weight loss in a cardiovascular trial population identifies people at future risk of dementia
por: van der Veere, P, et al.
Publicado: (2022)

Cellular and Structural Basis of Synthesis of the Unique Intermediate Dehydro-F420-0 in Mycobacteria
por: Rhys Grinter, et al.
Publicado: (2020-06-01)

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes
por: Praveen Patel, et al.
Publicado: (2025-02-01)